Superworth

Coherus Oncology CHRS

Biotechnology, Healthcare
$0.75
−9.72%
Market cap
$115.8M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.3×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$50.9M
+61% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
n/m
not a meaningful number

Coherus Oncology trades at 2.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $50.9M over the last twelve months, up 61% on a year earlier.

Charts

Financials

Income statement for CHRS, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$74.6M+64%$91.5M+102%$2.3M−93%$10.3M−83%$6.1M−92%$7.7M−92%$7.6M+229%$10.3M−0%$11.6M+91%$12.7M+65%$12.3M+62%$14.3M+40%
Cost of revenue$32.7M−7%$84.6M+496%$1.4M−92%$1.8M−93%$2.7M−92%$2.8M−97%$2.7M+84%$3.4M+88%$3.7M+36%$4M+47%$3.8M+44%$4.2M+25%
Gross profit$41.9M+311%$7M−78%$869K−94%$8.5M−75%$3.3M−92%$5M−28%$4.9M+469%$6.9M−19%$7.8M+136%$8.7M+75%$8.5M+72%$10.1M+47%
R&D$25.6M−44%$26.4M−9%$28.4M−17%$20.6M−12%$22.1M−14%$20.8M−21%$24.4M−14%$26.3M+28%$27.3M+24%$31M+49%$21.5M−12%$21.4M−19%
SG&A$48.2M+8%$49.5M−8%$40.2M−18%$27.5M−39%$28.1M−42%$29.6M−40%$26M−35%$26M−5%$24.9M−11%$23.6M−20%$23.1M−11%$21M−20%
−$32M−60%−$68.9M+34%−$67.8M+0%−$39.6M+15%−$46.9M+46%−$45.4M−34%−$45.4M−33%−$45.5M+15%−$44.3M−5%−$45.9M+1%−$36.2M−20%−$32.3M−29%
Interest expense$10.3M+36%$10.6M+13%$3.1M−68%$4.1M−59%$2.8M−73%$1.9M−82%$2.1M−31%$2.3M−44%$2.3M−18%$2.2M+18%$2.2M+2%$2.3M+2%
Pre-tax income−$40M−54%−$79.7M+35%−$68M−10%−$54.9M+28%−$47.6M+19%−$46.1M−42%−$47.4M−30%−$44.9M−18%−$44.5M−7%−$46.3M+1%−$36.9M−22%−$33.3M−26%
−$380K$0n/an/an/an/an/an/an/an/an/an/a
Net income−$39.6M−54%−$79.7M+35%$102.9M−$12.9M−70%−$10.8M−73%−$50.7M−36%−$56.6M$297.8M−$35.5M+231%−$37.6M−26%−$38.3M−32%−$20.6M
−$0.41−63%−$0.71−7%$0.91−$0.11−78%−$0.09−78%−$0.44−38%−$0.49$2.57−$0.31+244%−$0.31−30%−$0.28−43%−$0.13
97.7M+26%111.6M+43%112.7M+42%114.8M+32%115.2M+18%115.4M+3%115.9M+3%116.1M+1%116.2M+1%120.4M+4%136.4M+18%154.8M+33%

Gross profit: 29 periods, Q1 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 9 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 11 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19 and Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Coherus Oncology's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CHRSCoherus Oncology$115.8Mn/m8.9×2.3×+61%n/m
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
Peer median$140.6M14.1×19.8×1.8×+6%11.0%

More on Coherus Oncology

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .